Journal Article

FZJ-2021-00059

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Proven validity and management impact of amyloid imaging in Alzheimer’s disease—repetita juvant

Barthel, H. (Corresponding author) ; Arbizu, J. ; Drzezga, A.FZJ* ; Garibotto, V. ; Lammertsma, A. A. ; Morbelli, S.

2020
Springer-Verl. Heidelberg [u.a.]

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/32230  doi:10.1007/s00259-020-04742-w

Abstract: The Editorial “Suboptimal Validity of Amyloid Imaging-Based Diagnosis and Management of Alzheimer’s Disease: Why It Is Time to Abandon the Approach” which appeared online ahead of print on October 31, 2019, in the EJNMMI [1] has come to our attention. From our point of view, the topic of amyloid imaging is discussed in a biased and opinionated form in this Editorial. Some facts generally accepted by imaging experts and neuropathologists are questioned or neglected, which may leave the reader with a misleading impression that does not correspond with the current state of knowledge. The EANM Neuroimaging Committee, thus, feels the need to correct this impression in order to allow the reader to differentiate between commonly accepted scientific facts versus individual opinions and matters still unresolved, regarding the topic discussed. For space reasons, we will discuss here only the issues with the greatest risk for misleading interpretation.

---

Contributing Institute(s):

1. Molekulare Organisation des Gehirns (INM-2)

Research Program(s):

1. 572 - (Dys-)function and Plasticity (POF3-572) (POF3-572)
2. 573 - Neuroimaging (POF3-573) (POF3-573)

---

Database coverage:
; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---